Bowel cancer, also known as colorectal cancer, is the second most common cancer in Australian men and women. It affects 1 in 13 people. It is also Australia’s second deadliest cancer, with over 5,000 people dying each year. Early detection through screening can improve survival rates, however further research is needed to help find cures and prevent the disease.
The Bowel Cancer and Biomarker Laboratory at the Kolling Institute uses advanced technologies to study the genes and proteins responsible for bowel cancers growing and spreading. Our aim is to use a patient’s own molecular information to understand the risk of bowel cancer developing and to guide treatment options. As part of our research, we are studying how to control bowel polyp growth, which are precursors to cancer. We are doing this through diet and chemotherapy drugs.
The University of Sydney | Northern Clinical School
Faculty of Medicine and Health
Honorary Professor | Dept. Molecular Sciences, Macquarie University
Secretary | Australasian Proteomics Society
Postdoctoral Research Fellow
Postdoctoral Scientist
Matthew McKay - Senior Research Officer
Bharat Venkatesh Gunappa - Research Officer
Atul Bhatnagar - Senior Technical Officer
(Vo Van) Anh Pham - Honours Student
Miguel Castaneda - Research Assistant
Current bowel cancer research focuses on:
Our research is facilitated by specimens from clinical projects we run including:
Posted on: 13 March, 2023
With ovarian cancer continuing to have a devastating outcome for many women, new research at the Kol..... Read more
Category: New Treatment, Research Excellence
Posted on: 27 February, 2023
Kolling Institute Governance Committee Chair Michael Nugent said it is encouraging to see more than ..... Read more
Category: Research Excellence
Posted on: 20 February, 2023
A collection of emerging research leaders will have the chance to broaden their research experience ..... Read more
Category: Awards, Research Excellence